Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results
Key Highlights
- ➤Q3 total revenues $342 million, up 23% year-over-year
- ➤DAYBUE sales $140 million, up 39% year-over-year
- ➤NUPLAZID sales $202 million, up 14% year-over-year
- ➤2026 DAYBUE sales guidance raised to $505–$520 million
- ➤2026 R&D expense guidance lowered to $325–$340 million
Expert Statements
Catherine Owen Adams, Chief Executive Officer of Acadia Pharmaceuticals
“Acadia delivered a strong third quarter, with total revenues of $342 million and continued commercial momentum across DAYBUE and NUPLAZID.”
Catherine Owen Adams, Chief Executive Officer of Acadia Pharmaceuticals
“In the U.S., DAYBUE delivered another strong quarter, supported by meaningful uptake of DAYBUE STIX.”
Catherine Owen Adams, Chief Executive Officer of Acadia Pharmaceuticals
“In Europe, we are excited to build momentum following our recent launch of DAYBU in Germany.”
Catherine Owen Adams, Chief Executive Officer of Acadia Pharmaceuticals
“NUPLAZID also performed well, driven by underlying demand and the continued expansion of our commercial reach.”
Catherine Owen Adams, Chief Executive Officer of Acadia Pharmaceuticals
“Together, these growing franchises provide the commercial and financial foundation to advance clinical programs with the potential to become Acadia’s next meaningful growth opportunities.”
Catherine Owen Adams, Chief Executive Officer of Acadia Pharmaceuticals
“In Alzheimer’s disease psychosis, we are continuing Phase 3 development of remlifanserin based on Phase 2 results.”
Catherine Owen Adams, Chief Executive Officer of Acadia Pharmaceuticals
“As we look ahead to 2027, we anticipate two Phase 2 readouts: ACP-211 in major depressive disorder, and remlifanserin in Lewy body dementia psychosis, for which we are providing timing guidance for the first time.”
Catherine Owen Adams, Chief Executive Officer of Acadia Pharmaceuticals
“We look forward to sharing these updates as we continue to advance the next wave of our pipeline.”
Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results
- Third quarter GAAP total revenues of $342 million, up 22% year-over-year as compared to non-GAAP adjusted total revenues
Get started
Create a free account to read the full story.